Evidence map›Paper›PMID 34718761›Full record

ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2021

Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease.

Pedro H Imenez Silva, Robert Unwin, Ewout J Hoorn, Alberto Ortiz, Francesco Trepiccione, Rikke Nielsen, Vesna Pesic, Gaye Hafez, Denis Fouque, Ziad A Massy and 4 more

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Chemotherapy-related cognitive impairment and kidney dysfunction.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  6. CONNECT: what has been done and what needs to be done.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Physiological relevance of proton-activated GPCRs.Pflugers Archiv : European journal of physiology · 2022
    Review
  17. Present and future of CONNECT: a new and compelling project of modern medicine.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Article
  18. Brain dysfunction in tubular and tubulointerstitial kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 16 institutions in 11 countries.

Pedro H Imenez SilvaInstitute of Physiology, University of Zurich, Zürich, Switzerland.
Robert UnwinDepartment of Renal Medicine, Royal Free Hospital, University College London, London, UK.ORCID 0000-0001-7839-6031
Ewout J HoornDepartment of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-8738-3571
Alberto OrtizDepartment of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.ORCID 0000-0002-9805-9523
Francesco TrepiccioneBiogem Institute of Molecular Biology and Genetics, Ariano Irpino, Italy.
Rikke NielsenDepartment of Biomedicine-Anatomy, University of Aarhus, Aarhus, Denmark.
Vesna PesicDepartment of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Gaye HafezDepartment of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul, Turkey.ORCID 0000-0002-0837-634X
Denis FouqueCarMeN, INSERM 1060, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0002-9707-7199
Ziad A MassyDepartment of Nephrology, Ambroise Paré University Hospital, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt, France.
Chris I De ZeeuwDepartment of Neuroscience, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Giovambattista CapassoBiogem Institute of Molecular Biology and Genetics, Ariano Irpino, Italy.ORCID 0000-0003-3469-8614
Carsten A WagnerInstitute of Physiology, University of Zurich, Zürich, Switzerland.ORCID 0000-0002-9874-8898
CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
University of Campania "Luigi Vanvitelli" · ITUniversity of Zurich · CHAarhus University · DKAltınbaş University · TRCentre Hospitalier Universitaire Amiens-Picardie · FRErasmus MC · NLHospital Universitario Fundación Jiménez Díaz · ESInserm · FRThe Royal Free Hospital · GBUniversité Claude Bernard Lyon 1 · FRUniversity of Belgrade · RSCHU Ambroise Paré · BEErasmus University Rotterdam · NLHospices Civils de Lyon · FRNetherlands Institute for Neuroscience · NLUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic acidosis, defined as a plasma or serum bicarbonate concentration <22 mmol/L, is a frequent consequence of chronic kidney disease (CKD) and occurs in ~10-30% of patients with advanced stages of CKD. Likewise, in patients with a kidney transplant, prevalence rates of metabolic acidosis range from 20% to 50%. CKD has recently been associated with cognitive dysfunction, including mild cognitive impairment with memory and attention deficits, reduced executive functions and morphological damage detectable with imaging. Also, impaired motor functions and loss of muscle strength are often found in patients with advanced CKD, which in part may be attributed to altered central nervous system (CNS) functions. While the exact mechanisms of how CKD may cause cognitive dysfunction and reduced motor functions are still debated, recent data point towards the possibility that acidosis is one modifiable contributor to cognitive dysfunction. This review summarizes recent evidence for an association between acidosis and cognitive dysfunction in patients with CKD and discusses potential mechanisms by which acidosis may impact CNS functions. The review also identifies important open questions to be answered to improve prevention and therapy of cognitive dysfunction in the setting of metabolic acidosis in patients with CKD.

Indexed as

AcidosisCognitive DysfunctionMotor DisordersRenal Insufficiency, ChronicBicarbonatesHumansBicarbonatesacidosischronic kidney diseasecognitive dysfunctionklothomotor function

Identifiers

PMID34718761
PMCPMC8713149
OpenAlexW3208218618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.